Watch the interview with Aqilion’s Chairman Bertil Lindmark below.
Chairman envisions continued success for Aqilion
Aqilion, led by CEO Sarah Fredriksson, focuses on developing new treatments for diseases caused by chronic inflammation. In February, the company announced a major licensing deal and strategic collaboration with Merck. The deal, worth upwards of EUR 950 million, is aimed at the discovery, development and commercialisation of TAK1 protein inhibitors. The company’s Chairman, Bertil Lindmark, visited the BioStock Studio to talk about his vision for the company and ambitions for continued success.
Notiser
PHI får ny vd
AcouSort utökar europeiskt samarbete
Integrum stärker distribution i Ukraina
Active Biotech säkrar patent för tasquinimod
Alligator undantas krav på pediatriska studier
NYHETSBREV
NYHETER
Biosergen avancerar sin kandidat med starka Q1-resultat
Novo Holdings toppar läkemedelssektorns VC-lista
Aptahem rapporterar partnerintresse från europeiskt läkemedelsbolag
Kommande event!
Global Forum
Expand your understanding of new markets, striking global partnerships and attracting international capital. Find new opportunities and learn how to...
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
Krönikor
Första draget gjort – nu väntar vi på svar
Osäkerheten gör det svårare att deala
